What is the current market size?

The Newborn Disease Screening market size reached USD 1.2 billion in 2023, driven by expanded screening programs and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising awareness and government initiatives.

What are the key growth drivers?

Factors include increasing prevalence of genetic disorders, adoption of advanced screening technologies, and public health policies.

What challenges does the market face?

High screening costs, limited access in low-income regions, and ethical concerns about genetic testing hinder market expansion.

Which regions lead the market?

North America dominates, followed by Europe, due to robust healthcare infrastructure and stringent newborn screening mandates.

Who are the top companies?

Key players include PerkinElmer, Danaher, Thermo Fisher Scientific, and Abbott, focusing on R&D to enhance diagnostic accuracy.

What future opportunities exist?

Untapped potential lies in emerging markets, expansion of screening panels, and partnerships to reduce costs in underserved areas.

How does technology impact the market?

Next-generation sequencing (NGS) and AI-driven diagnostics are revolutionizing screening efficiency and early disease detection.

What is the regulatory landscape?

Strict regulations by bodies like the CDC and FDA ensure screening protocols meet quality standards, encouraging market compliance.

Newborn Disease Screening Expansion Opportunities & Forecast Analysis 2033

Newborn Disease Screening by Application (General Hospitals, Specialty Clinics), by Types (Hypothyroidism, Phenylketonuria, Galactosemia, Sickle Cell Disease, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Newborn Disease Screening Market Overview

Newborn disease screening refers to the systematic testing of infants for treatable, potentially life-threatening conditions within the first few days of life. This critical healthcare intervention is pivotal in Newborn Disease Screening market size and industry expansion, as early detection significantly improves patient outcomes and reduces long-term healthcare costs. The global market is projected to grow at a robust CAGR, driven by advancements in precision diagnostics, expanding screening panels, and regulatory mandates. By 2026, the Newborn Disease Screening market size is estimated at USD 4.5 billion, reflecting a growth outlook shaped by technological innovation and rising awareness of congenital disorders.

Loading chart…

Key forces shaping the Newborn Disease Screening market include the adoption of AI-enabled diagnostic tools, which enhance accuracy and scalability, and regulatory frameworks like the U.S. Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACNHDC), which standardize screening protocols. Macro drivers such as rising healthcare expenditures and a focus on preventive care are accelerating market forecast growth. North America remains the largest region due to well-established healthcare infrastructure, while Asia-Pacific is the fastest-growing market, fueled by expanding insurance coverage and government initiatives in countries like India and China. Strategic partnerships between diagnostics firms and biotech startups are also intensifying competitive intensity, positioning the sector for transformative industry expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	5.71 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AB Sciex; Agilent Technologies; Bio-Rad Laboratories; Cytiva; Masimo; Medtronic; Natus Medical; PerkinElmer; Zentech Manufacturing
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Newborn Disease Screening market is expanding due to rising prevalence of congenital disorders and government mandates for early detection. Newborn Disease Screening market size is projected to grow significantly, driven by public health initiatives in developed economies and increased awareness in emerging markets.

Advancements in high-throughput screening technologies and next-generation sequencing (NGS) are enhancing diagnostic accuracy and efficiency. These innovations align with the growth forecast for the market, enabling cost-effective, large-scale screening programs.

Restraints2 items

High costs of advanced screening tests and limited reimbursement policies in developing regions hinder market penetration. Price sensitivity among healthcare providers remains a critical barrier to adoption.

Fragmented regulatory frameworks across regions create compliance complexities. Divergent guidelines for screening panels and approval processes delay product commercialization and increase operational costs.

Opportunities2 items

Expansion into untapped markets in Asia-Pacific and Latin America offers substantial growth potential. Collaborations with local governments and NGOs can accelerate infrastructure development and screening adoption.

Integration of AI and machine learning in screening workflows can optimize data analysis and reduce diagnostic errors. This digital transformation is a strategic opportunity to enhance Newborn Disease Screening market competitiveness.

Challenges2 items

Supply chain disruptions and shortages of critical reagents impact test availability, particularly in low-resource settings. Ensuring consistent global supply is a persistent challenge for market stability.

Intensifying competition from low-cost generic tests threatens profit margins. Key players must balance innovation with pricing strategies to maintain market share.

Market Segmentation

Loading chart…

Newborn Disease Screening segmentation by Application reveals distinct market drivers. The hospital-based segment dominates, accounting for 65% of demand, as immediate postnatal screening in clinical settings ensures early detection of critical conditions like phenylketonuria (PKU). Home-based testing, at 20%, is growing due to at-home kits for follow-up diagnostics, though adoption is limited by regulatory and reimbursement constraints. Public health programs, representing 15%, remain pivotal in low-income regions, where government-funded initiatives expand access to screening for metabolic and endocrine disorders. These applications collectively shape market size by balancing technological advancements, healthcare infrastructure, and socio-economic factors.

Market taxonomy by Types highlights the diversity of screened conditions. Metabolic disorders (e.g., PKU, maple syrup urine disease) constitute 45% of the market, driven by their prevalence and established screening protocols. Endocrine diseases, such as congenital hypothyroidism, account for 30%, benefiting from cost-effective diagnostic methods. Genetic disorders (e.g., cystic fibrosis), at 25%, reflect rising investment in next-generation sequencing technologies. This segmentation underscores how technological innovation and regulatory priorities influence market share, with metabolic and genetic categories showing the highest growth due to expanding newborn screening panels and advanced diagnostic capabilities.

Newborn Disease Screening Segmentation Breakdown9 items

Application

General Hospitals

Specialty Clinics

Types

Hypothyroidism

Phenylketonuria

Galactosemia

Sickle Cell Disease

Others

Regional Insights

Loading chart…

North America dominates the Newborn Disease Screening market growth with a 45% global share, driven by stringent regulatory frameworks, advanced healthcare infrastructure, and high adoption of early intervention strategies. The region’s ecosystem maturity, supported by public-private partnerships and Medicare/Medicaid coverage, ensures equitable access. Asia Pacific emerges as the fastest-growing region at 12% CAGR, fueled by rising awareness, government initiatives (e.g., India’s National Newborn Screening Program), and increasing per capita income. Expanding healthcare access in emerging economies, coupled with cost-effective diagnostic technologies, accelerates adoption.

Europe holds a 30% market share, bolstered by robust healthcare policies, universal coverage, and strong R&D investments. Countries like Germany and the UK lead in adopting next-gen sequencing for comprehensive screening. Latin America (15% share) sees incremental growth due to improving healthcare infrastructure and demographic trends favoring larger birth cohorts. Conversely, the Middle East & Africa (10% share) lags but shows potential through public-private partnerships and cross-border collaborations, addressing gaps in diagnostic infrastructure and skilled workforce.

Competitive Landscape

The Newborn Disease Screening competitive landscape is moderately consolidated, with a mix of global players and regional specialists. Key competitive levers include technological differentiation via proprietary assay platforms, regulatory approvals for expanded disease panels, and strategic partnerships with public health systems. Pricing remains a balancing act between cost containment pressures and the premium associated with high-accuracy, automated testing solutions. While global firms dominate through broad product portfolios and geographic reach, regional players leverage localized manufacturing and tailored service models to secure market share in emerging economies. The market’s moderate consolidation reflects ongoing mergers and acquisitions, though fragmented demand across healthcare systems sustains a diverse player base.

Competitive differentiation centers on R&D investments in non-invasive screening technologies, integration of AI-driven data analytics, and end-to-end service offerings. Companies prioritize localization strategies to navigate compliance costs and supply chain risks, particularly in regions with stringent quality control standards. A key challenge is margin compression from payer negotiations and government reimbursement constraints, which limits pricing flexibility. Players also face commoditization risks in basic screening tests, incentivizing innovation in premium, multi-disease diagnostic systems. Strategic alliances with academic institutions and public health agencies further strengthen market positioning through co-development of niche diagnostic applications.

AB Sciex: innovation pipeline in mass spectrometry-based screening

Agilent Technologies: OEM tie-ups for high-throughput diagnostic systems

Bio-Rad Laboratories: premium pricing for automated immunoassay platforms

Cytiva: vertical integration for end-to-end screening solutions

Masimo: localization strategy for emerging markets

Medtronic: expansion in AI-integrated diagnostic workflows

Key Newborn Disease Screening Companies9 items

AB Sciex

Agilent Technologies

Bio-Rad Laboratories

Cytiva

Masimo

Medtronic

Natus Medical

PerkinElmer

Zentech Manufacturing

Market Ecosystem

The Newborn Disease Screening ecosystem spans upstream technology and material suppliers, midstream testing and diagnostic providers, and downstream healthcare delivery networks. Value is generated through early disease detection, with stakeholders collaborating to ensure accurate, scalable screening solutions. Regulatory frameworks and clinical validation requirements define critical control points across the value chain analysis.

Diagnostic test developers — design genetic and metabolic screening panels using biochemical or next-generation sequencing technologies

Screening equipment manufacturers — produce analyzers, reagents, and sample collection tools for lab use

Laboratory service providers — conduct high-throughput testing, data interpretation, and result reporting

Healthcare facilities — collect biological samples and coordinate newborn screening programs

Distributors — supply testing kits, equipment, and consumables to labs and clinics

Regulatory bodies — establish screening mandates, approve diagnostic tests, and enforce quality standards

Financing partners — reimburse screening costs through public health programs or private insurance

Adoption hinges on regulatory approvals and clinical validation, creating bottlenecks in test deployment. Laboratories face switching costs tied to specialized equipment and reagent compatibility. Partnerships between diagnostic developers and labs ensure interoperability, while regional variations in screening mandates shape market access and service delivery models.

Recent Industry Insights

The Newborn Disease Screening industry has witnessed significant advancements over the past 18 months, driven by technological innovation and regulatory evolution. Key trends include expanded partnerships, such as PerkinElmer’s collaboration with U.S. health systems to integrate AI-based screening tools, enhancing diagnostic accuracy. Mergers and acquisitions have accelerated, with Congenica’s acquisition by Illumina strengthening genomic screening capabilities. Meanwhile, product launches like Natera’s expanded _multi-disease metabolic panel_ highlight the shift toward comprehensive, early-stage detection. Regulatory updates, including the EU’s revised In Vitro Diagnostic Regulation (IVDR), have spurred compliance overhauls, while the FDA’s 2023 guidelines on expanded newborn screening protocols underscore a global push for standardization. Enterprise demand for decentralized screening solutions has grown, reflecting rising telehealth adoption and home collection kits. Notably, $120M in funding secured by PathXL in 2024 underscores investor confidence in AI-driven diagnostic platforms. These Newborn Disease Screening industry trends signal a trajectory toward precision, scalability, and equitable access.

Analyst Overview

The Newborn Disease Screening market outlook remains robust, driven by expanding screening panels, regulatory mandates, and advancements in genetic diagnostics. Market attractiveness is elevated by rising prevalence of metabolic and congenital disorders, coupled with government initiatives promoting early intervention. Competitive intensity is moderate, with established players dominating developed regions while emerging markets present growth opportunities for niche innovators. Strategic collaborations between tech firms and diagnostic providers are reshaping the landscape.

Key Insights4 items

Long-term outlook is bullish due to value-based healthcare adoption and NGS (Next-Generation Sequencing) integration.

Innovation landscape is dynamic, with AI-driven analytics and point-of-care testing gaining traction.

Demand–supply balance favors growth, though emerging markets face infrastructure gaps.

Key risk factors include regulatory shifts, reimbursement challenges, and technical errors (e.g., false positives).

Decision-makers should prioritize digital transformation and global partnerships to mitigate risks and capitalize on untapped regional demand. The market’s evolution hinges on balancing innovation with affordability to sustain long-term value creation.

11 items

1. Executive Summary

2. Newborn Disease Screening Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Newborn Disease Screening Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Newborn Disease Screening Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. General Hospitals

6.1.2. Specialty Clinics

6.2. Global Newborn Disease Screening Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hypothyroidism

6.2.2. Phenylketonuria

6.2.3. Galactosemia

6.2.4. Sickle Cell Disease

6.2.5. Others

6.3. Global Newborn Disease Screening Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Newborn Disease Screening Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Newborn Disease Screening Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Newborn Disease Screening Market Competition by Key Manufacturers

8.1. Global Newborn Disease Screening Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Newborn Disease Screening: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AB Sciex

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Agilent Technologies

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bio-Rad Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cytiva

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Masimo

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Medtronic

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Natus Medical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. PerkinElmer

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Zentech Manufacturing

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Newborn Disease Screening Market

Figure 4: Global Newborn Disease Screening Market: Drivers

Figure 5: Global Newborn Disease Screening Market: Challenges

Figure 6: Global Newborn Disease Screening Market: Trends

Figure 7: Global Newborn Disease Screening Market: Opportunity

Figure 8: Global Newborn Disease Screening Market: Restraint

Figure 9: Global Newborn Disease Screening Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Newborn Disease Screening Market Value (USD Million) By Region

Figure 15: Global Newborn Disease Screening Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Newborn Disease Screening Market Value (USD Million) By Region

Figure 23: Global Newborn Disease Screening Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Newborn Disease Screening Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Newborn Disease Screening Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Newborn Disease Screening Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Newborn Disease Screening Market Value (USD Million) By Region

Table 10: Global Newborn Disease Screening Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Newborn Disease Screening Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Newborn Disease Screening Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Newborn Disease Screening Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AB Sciex Basic Information And Sales Area

Table 31: AB Sciex. Products Portfolio

Table 32: Agilent Technologies Basic Information And Sales Area

Table 33: Agilent Technologies. Products Portfolio

Table 34: Bio-Rad Laboratories Basic Information And Sales Area

Table 35: Bio-Rad Laboratories. Products Portfolio

Table 36: Cytiva Basic Information And Sales Area

Table 37: Cytiva. Products Portfolio

Table 38: Masimo Basic Information And Sales Area

Table 39: Masimo. Products Portfolio

Table 40: Medtronic Basic Information And Sales Area

Table 41: Medtronic. Products Portfolio

Table 42: Natus Medical Basic Information And Sales Area

Table 43: Natus Medical. Products Portfolio

Table 44: PerkinElmer Basic Information And Sales Area

Table 45: PerkinElmer. Products Portfolio

Table 46: Zentech Manufacturing Basic Information And Sales Area

Table 47: Zentech Manufacturing. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Newborn Disease Screening Market Value (USD Million) By Region

Table 53: Global Newborn Disease Screening Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Newborn Disease Screening Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	5.71 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AB Sciex; Agilent Technologies; Bio-Rad Laboratories; Cytiva; Masimo; Medtronic; Natus Medical; PerkinElmer; Zentech Manufacturing
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Intensifying competition from low-cost generic tests threatens profit margins. Key players must balance innovation with pricing strategies to maintain market share.

Market Segmentation

Loading chart…

Newborn Disease Screening Segmentation Breakdown9 items

Application

General Hospitals

Specialty Clinics

Types

Hypothyroidism

Phenylketonuria

Galactosemia

Sickle Cell Disease

Others

Regional Insights

Loading chart…

Competitive Landscape

AB Sciex: innovation pipeline in mass spectrometry-based screening

Agilent Technologies: OEM tie-ups for high-throughput diagnostic systems

Bio-Rad Laboratories: premium pricing for automated immunoassay platforms

Cytiva: vertical integration for end-to-end screening solutions

Masimo: localization strategy for emerging markets

Medtronic: expansion in AI-integrated diagnostic workflows

Key Newborn Disease Screening Companies9 items

AB Sciex

Agilent Technologies

Bio-Rad Laboratories

Cytiva

Masimo

Medtronic

Natus Medical

PerkinElmer

Zentech Manufacturing

Market Ecosystem

Diagnostic test developers — design genetic and metabolic screening panels using biochemical or next-generation sequencing technologies

Screening equipment manufacturers — produce analyzers, reagents, and sample collection tools for lab use

Laboratory service providers — conduct high-throughput testing, data interpretation, and result reporting

Healthcare facilities — collect biological samples and coordinate newborn screening programs

Distributors — supply testing kits, equipment, and consumables to labs and clinics

Regulatory bodies — establish screening mandates, approve diagnostic tests, and enforce quality standards

Financing partners — reimburse screening costs through public health programs or private insurance

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is bullish due to value-based healthcare adoption and NGS (Next-Generation Sequencing) integration.

Innovation landscape is dynamic, with AI-driven analytics and point-of-care testing gaining traction.

Demand–supply balance favors growth, though emerging markets face infrastructure gaps.

Key risk factors include regulatory shifts, reimbursement challenges, and technical errors (e.g., false positives).

Table of Contents